Clinical trials: Opioid Related Disorders
Opioid-Related Disorders, Opiate Dependence
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
The purpose of the study was to assess the efficacy of induction treatment with buprenorphine/naloxone (BNX) sublingual tablet s compared with induction treatment with buprenorphine only.
- Trial name
- NCT01848054
- Testing
- Buprenorphine/naloxone sublingual tablets, Buprenorphine
- Where
- 14 sites in United States
- Volunteers
- 313 people
- Sponsor
- Orexo AB
Opioid Dependence
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
The primary objective of the study is to demonstrate maintenance of treatment efficacy when transferring adult outpatients with opioid dependence, who are clinically stabilized on 8 mg or less of sublingual (SL) buprenorphine…
- Trial name
- PRO-814 (NCT02180659)
- Testing
- sublingual buprenorphine tablets, Buprenorphine implant
- Volunteers
- 177 people
- Sponsor
- Titan Pharmaceuticals
Opioid Dependence
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid dependence is a substantial problem associated with significant morbidity and mortality. Extended-release naltrexone has been found effective at reducing opioid use and maintaining abstinence, but its use has been limited…
- Trial name
- NCT02437344
- Testing
- CI-581aa, Naltrexone titration and XR-NTX initiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder
Contingency Management to Enhance Office-Based Buprenorphine Treatment
Contingency Management interventions provide incentives to substance abuse patients when patients meet therapeutic goals. This project will compare the effectiveness of two Contingency Management interventions (which the…
- Trial name
- NCT04024059
- Testing
- Contingency Management for adherence, Contingency Management for abstinence
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Johns Hopkins University
Opioid-use Disorder
Buprenorphine Treatment Engagement and Overdose Prevention
Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use…
- Trial name
- NCT03677986
- Testing
- Video DOT+
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Johns Hopkins University
Stigma, Social, Opioid Use
SMART Trial: Intrapersonal and Interpersonal Stigma Reduction
The goal of this project is to develop a multicomponent stigma reduction intervention to address intrapersonal (individual) stigma regarding Opioid Use Disorder (OUD).
- Conditions
- Stigma, Social, Opioid Use, Opioid-use Disorder, Substance Use Disorders
- Trial name
- NCT04693416
- Testing
- Intrapersonal Stigma Reduction, Interpersonal Stigma Reduction
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of Tennessee
Opioid-use Disorder
Stress Response in Opioid Use Disorder
Opioid use disorder is a major public health problem. Although there are effective treatments for this disorder, many people still relapse and thus there is a need for new treatments to improve outcomes.
- Trial name
- NCT03616379
- Testing
- Psychoeducational Control, Affect Regulation, Affect Labelling
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Mclean Hospital
Opioid-Induced Bowel Dysfunction
Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone
The purpose of this study is to evaluate the long-term safety and efficacy of lubiprostone administration in participants with opioid-induced bowel dysfunction.
- Trial name
- NCT00620061
- Testing
- Lubiprostone 24
- Where
- 123 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Sucampo Pharma Americas, LLC
Drug Dependence
Extended Release Naltrexone for Opioid-Dependent Youth
The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).
- Trial name
- NCT01843023
- Testing
- Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
- Where
- 2 sites in United States
- Volunteers
- 288 people
- Sponsor
- Friends Research Institute, Inc.
Opioid-Related Disorders, Heroin Dependence
Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder
The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel paired-neuromodulation approaches using transcrancial direct…
- Conditions
- Opioid-Related Disorders, Heroin Dependence, Morphine Dependence
- Trial name
- NCT04495673
- Testing
- Transcranial Direct Current Stimulation (tDCS), Cognitive Training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Minnesota
Constipation
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01275755
- Testing
- ADL5945 0.25 mg
- Volunteers
- 81 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid-use Disorder
Disclosure Intervention for People in Recovery From Opioid Use Disorder
Many people with substance use disorders struggle with decisions regarding whether to disclose to others that they have a history of substance use and/or are in recovery.
- Trial name
- NCT04836247
- Testing
- Disclosing Recovery: A Decision Aid and Toolkit, Mindfulness
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Delaware
Opiate Dependence, Heroin Dependence
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
In pilot study now proposed, we plan to randomly assign 60 opioid dependent patients to the new model, Depot-BNT, or to BNT plus oral naltrexone for a 6-month trial.
- Trial name
- Depot-BNT (NCT00577408)
- Testing
- depot naltrexone, Oral Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
HIV, Opioid Dependence
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
To conduct a randomized clinical trial (RCT) of a community-friendly behavioral intervention designed to reduce HIV risk behavior among injection drug users (IDUs) in drug treatment by comparing risk-behavior outcomes of four…
- Trial name
- NCT01741350
- Testing
- Community-friendly Health Recovery Program, Time-and-Attention-Matched Control Condition
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- University of Connecticut
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opiate Addiction, Pregnancy
Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy
This study is a pharmacodynamic study in pregnant women evaluating the relationship between buprenorphine concentration and outcome such as opioid withdrawal symptoms , NAS scores, neurodevelopmental and neuroanatomic outcomes.
- Trial name
- NCT03831113
- Testing
- Magnitude Group, Frequency Group
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Steve N. Caritis, MD
Heroin Dependence, Opioid-Related Disorders
Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry
The purpose of this study is to compare the effectiveness of extended-release naltrexone (XR-NTX) vs. enhanced treatment-as-usual (TAU) among opioid dependent adults leaving NYC jails.
- Trial name
- XOR (NCT01999946)
- Testing
- Extended-Release Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 217 people
- Sponsor
- NYU Langone Health
Heroin Dependence
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT01760473
- Testing
- Intranasal challenge drug
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Post Traumatic Stress Disorder, Opioid-use Disorder
Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
Among patients with opioid use disorder (OUD), 90% report lifetime trauma exposure and 33% meet criteria for posttraumatic stress disorder (PTSD).
- Trial name
- NCT04104022
- Testing
- Prolonged Exposure Therapy, Attendance-based monetary incentives
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Vermont